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Abstract The E2 transcriptional activator of the human pap-
illomavirus regulates the expression of most viral transcripts. Its
binding to speci¢c target DNA sequences involves large confor-
mational changes in the interacting macromolecules. The high
stability of the E2:DNA complex prompted us to analyze the
role of macromolecular interactions and adjuvant emulsions in
the appearance of conformation-speci¢c antibodies. We demon-
strate that immunization with free or DNA-complexed E2 emul-
si¢ed in an oil-in-water adjuvant elicits a humoral response
shifted to the recognition of discontinuous epitopes. Epitope
mapping and functional analysis of the generated anti-E2
mAbs reveals that two separate antibodies populations can be
obtained: those able to form a stable ternary complex with
protein and DNA, and those which recognize the DNA-binding
surface of the transcription factor, interfering with E2 binding
to DNA.
' 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The E2 transcriptional activator of the human papilloma-
virus (HPV) regulates the expression of most viral transcripts,
and plays an auxiliary role in viral DNA replication [1]. In-
fection with the high-risk strains (HPV-16, 18, 31 and 33) is
strongly associated with various cancers of the ano-genital
tract, particularly cervical carcinomas. The E2 C-terminal
DNA-binding and dimerization domain (E2C) binds to par-
ticular recognition sequences on the viral genome. It was dem-
onstrated that binding of recombinant HPV-16 E2C to its
cognate double-stranded 18 bp oligonucleotide (site 35) in-
duces a conformational change in the protein, including a
large stabilizing e¡ect [2]. Besides, spectro£uorometric studies
show that this interaction is extremely stable, with a dissoci-
ation constant of about 0.2 nM [3].
Macromolecular interactions are crucial for stabilizing or
changing the conformation of the interacting partners. These
changes are detected by the immune system, which develops
speci¢c antibodies against the newly exposed conformational
epitopes. For example, the interaction of the HIV envelope
protein gp120 with the extracellular domain of CD4 and the
CCR5 chemokine receptor provokes a marked conformation-
al change on the HIV gp120 and gp41 proteins, resulting in
fusion of the virus and T cell membranes [4]. As a conse-
quence, B cells secreting antibodies speci¢c to these new con-
formational epitopes start to proliferate.
Given the high stability of the E2C:site 35 complex [2], and
the described conformational changes that occur upon com-
plex formation, this complex constitutes an excellent model to
study the immunogenic e¡ect of a protein:DNA complex on
the generation of conformation-speci¢c antibodies against the
interacting macromolecules. In a previous work [5] we have
shown that immunization with this protein:DNA complex
allowed us to obtain sequence-speci¢c, high-a⁄nity anti-oli-
gonucleotide antibodies. In this work we describe the e¡ect of
adjuvant composition and complex formation on the induced
anti-E2C response. Besides, we show that the generated anti-
E2C monoclonal antibodies (mAbs) recognize two main dif-
ferent surfaces on the transcription factor.
2. Materials and methods
2.1. E2C and DNA
The C-terminal 80-amino acid DNA-binding domain of the E2
protein from HPV-16 was expressed and puri¢ed as a soluble folded
dimeric protein as previously described [3]. The sequence of the A
chain of the synthetic oligonucleotide (IDT, USA) is 5P-GTAACC-
GAAATCGGTTGA-3P, corresponding to the E2 site 35 in the HPV-
16 genome. Fluoresceinated site 35 (FITC^site 35) contains a £uores-
cein molecule attached to the 5P end via a 6-carbon linker of the B
chain. Biotinylated site 35 (Bio-site 35) contains a biotin molecule
attached to the 5P end of the A chain. Single stranded oligonucleotide
concentration determination and annealing were carried out as de-
scribed [3].
2.2. Immunization protocols
For E2C immunizations, each mouse received intraperitoneally (IP)
16 Wg of the protein emulsi¢ed in the oil-in-water MPL0+TDM Ad-
juvant System (MPL) [6] (E2C/MPL) or in the water-in-oil Complete
Freund Adjuvant (E2C/FA) [7]. Second and third boosters were ad-
ministered with similar doses at intervals of 20-days. Incomplete
Freund Adjuvant was used in second and third boosters of the FA
protocol. Mice immunized with the E2C:site 35 complex received IP
25 Wg of the 1:1 mixture emulsi¢ed in MPL (E2C:site 35/MPL).
2.3. Production and puri¢cation of antibodies and Fabs
Splenocytes obtained from the immunized mice with the highest
titers were fused with a NSO mouse plasmacytoma cell line following
established techniques [8]. Hybridoma cultures producing anti-DNA-
and anti-E2C-speci¢c immunoglobulins were detected by enzyme-
linked immunosorbent assay (ELISA) and cloned to ensure mono-
clonality. mAb IgGs were prepared following standard procedures [9].
2.4. Heat denaturation of E2C
Puri¢ed E2C protein in 50 mM sodium acetate, pH 5.6, was incu-
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bated for 1 h at 85‡C, and then centrifuged for 15 min at 13 000 rpm.
Protein concentration of the sample before and after the treatment
remained unchanged. Fluorescence spectra of untreated and heat-de-
natured E2C were recorded in an Aminco Bowman series 2 lumines-
cence spectrometer. Excitation wavelength was ¢xed at 280 nm, and
the emission spectrum was recorded from 310 to 410 nm. The temper-
ature was set at 25P 0.1‡C.
2.5. ELISA assays
ELISA plates were sensitized with the di¡erent antigens for 1 h at
room temperature in Tris-bu¡ered saline (TBS), unless speci¢ed. The
di¡erent coating antigens used were 0.5 Wg/well E2C, 0.5 Wg/well of
thermally denatured E2C in 50 mM sodium acetate, pH 5.6, 0.5 Wg/
well of a 1:1 E2C:site 35 complex and 1 Wg/well of E2C peptides. In
the last case, the plate was incubated overnight at 37‡C. Sera from
mice were diluted in bovine serum albumin (BSA)/TBS, and their
reactivity was developed by incubating with peroxidase-conjugated
polyclonal antibodies to murine IgG Fc fragment (Accurate, USA).
2.6. Electrophoretic mobility shift assay
Samples containing 25 mM Bis-Tris^HCl, pH 7.0, 200 mM NaCl,
1 mM dithiothreitol (DTT), 8% glycerol, 2.5 WM E2C and the di¡er-
ent anti-E2C IgG mAbs (4 WM maximal concentration of binding
sites) were incubated for 2 h at room temperature. Next, 2.5 WM 5P
£uorescein^site 35 oligonucleotide was added and let to equilibrate for
30 min more in a ¢nal volume of 15 Wl. Mixtures were loaded in a 6%
polyacrylamide native gel containing 2.5% glycerol, 25 mM Tris^HCl,
pH 8.3, 190 mM glycine, 1 mM DTT. The gel was resolved at 5 V/cm
for approximately 2 h. Fluorescein bands were detected by UV trans-
illumination and documentation (UVP transilluminator system,
GDS8000).
2.7. Biosensor analysis of mAbs e¡ect on protein^DNA interaction
The e¡ect of the anti-protein mAbs on E2C binding to the site 35
oligonucleotide was analyzed in an Iasys plus A⁄nity Sensor Biosen-
sor from ThermoLabsystems. Immobilization of streptavidin was car-
ried out using the EDC/NHS Coupling Kit. Fifty Wl of bu¡er (25 mM
Bis-Tris^HCl, pH 7.0, 200 mM NaCl, 1 mM DTT, 1% BSA, 0.005%
Tween 20) were placed in the cuvette and 2.2 Wl of Bio-site 35 oligo-
nucleotide (5 Wg/ml ¢nal concentration) was let to equilibrate for
approximately 20 min. The change in resonance position noted was
10 arcsec response units. Binding of 0.1 WM E2C (¢nal concentration)
with or without previous incubation for 2 h with increasing concen-
trations of di¡erent IgG anti-E2C mAbs was followed for 5 min. In
any case, E2C binding to Bio-site 35 was considered as the di¡erence
in arcsec response between t0 and t5 min. At the beginning of each
experiment, E2C binding to the immobilized oligonucleotide was con-
sidered as the maximal response.
3. Results and discussion
Despite the importance of adjuvants for raising an immune
response, limited information concerning the e¡ects they
cause on antigen conformation is available in the literature.
We have previously shown that immunization with the
E2C:site 35 protein:DNA complex induces a strong anti-
DNA polyclonal response, prompting us to production of
mAbs [5]. Since we had used the oil-in-water MPL+TDM
adjuvant to emulsify the protein:DNA complex, we further
analyzed whether the presence of the cognate DNA or alter-
natively the composition of the adjuvant had a¡ected both the
immunogenicity of the protein and the pattern of reactivity of
the induced anti-E2C antibodies. To this purpose, a compar-
ative study of the antibody response elicited by three di¡erent
immunization protocols was carried out. The animals were
immunized with the E2C:site 35 complex (E2C:site 35/
MPL) or E2C alone (E2C/MPL) in MPL+TDM adjuvant,
or with free E2C in the water-in-oil Freund Adjuvant (E2C/
FA).
As can be seen in Fig. 1B, E2C is highly immunogenic. E2C
emulsi¢ed in Freund Adjuvant renders high IgG anti-E2C
titers (1/400 000), whereas E2C emulsi¢ed in MPL elicits titers
similar to the E2C:DNA complex in the same adjuvant (1/
150 000 average titers). E2 has been stated as the most immu-
no-reactive of all the HPV-16 proteins [10]. In accordance
with that report, our results show that high anti-E2C titers
were developed in the sera of all immunized mice, despite the
immunization protocol applied.
The e¡ect caused by two di¡erent adjuvant compositions on
the pattern of reactivity of the elicited antibodies was tested
by comparing sera titers against the native and denatured
forms of E2C. Fig. 1A shows the tryptophan £uorescence
spectra of the native and heat-denatured E2C. The decrease
in intrinsic tryptophan £uorescence and the shift to the red of
the center of mass indicate that the protein is irreversibly
denatured by high temperature at acidic pH (see Section 2,
[11]). As shown in Fig. 1B, MPL shifts the response towards
the recognition of discontinuous epitopes on E2C, irrespective
of the presence of the cognate oligonucleotide (compare E2C/
MPL and E2C:site 35/MPL titration curves). In contrast,
Freund Adjuvant causes at least a partial denaturation of
the protein, as noticed by the high polyclonal sera reactivity
against heat-denatured E2C (ELISA titers 1/10 000 and 1/400
for E2C/FA and E2C/MPL, respectively).
Fig. 1. A: Fluorescence tryptophan spectra of native (solid line) and
heat-denatured (dashed line) E2C. B: Polyclonal IgG response to-
wards native (closed symbols) or heat-denatured (open symbols)
E2C. Sera titration curves of mice immunized with free E2C and
E2C complexed with DNA in MPL+TDM adjuvant (E2C/MPL,
circles; E2C:site 35/MPL, triangles, respectively), or with free E2C
in Freund Adjuvant (E2C/FA, squares).
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From a E2C:site 35/MPL-immunized mouse, we made a
fusion experiment to obtain monoclonal anti-E2C and anti-
DNA antibodies. All 92 hybridoma culture supernatants
showed IgG anti-E2C:DNA and anti-E2C reactivity, whereas
15/92 cultures exhibited IgG anti-site 35 oligonucleotide reac-
tivity as determined by indirect ELISA. From those cultures,
we have cloned and studied six anti-E2C mAbs (named ED5,
ED12, ED13, ED15, ED19 and ED23), all of them from the
IgG1, k isotype.
In coincidence with the analysis of the polyclonal response,
most mAbs obtained from E2C:site 35/MPL-immunized mice
also recognize discontinuous epitopes. As shown in Fig. 2A,
¢ve of the six anti-E2C mAbs (ED5, 12, 13, 15 and 19) exhibit
a marked decrease in reactivity following thermal denatura-
tion of the protein. Accordingly, they did not react with E2C-
derived peptides covering the entire E2C sequence (see Fig.
2B). By contrast, ED23 was the only mAb that recognized
both native and denatured E2C. Moreover, it strongly reacted
against a 10 amino acids long peptide mapping to the C-ter-
minus of E2C, comprising residues 349^358 of the polypeptide
chain.
It was previously demonstrated that sera of animals immu-
nized with lysozyme emulsi¢ed in Freund Adjuvant strongly
reacted with both the native and denatured forms of the pro-
tein [13]. The author hypothesized that some denaturation of
the protein may have occurred during emulsi¢cation, since
antisera of animals immunized with the protein alone did
not react with the denatured antigen. On the other hand,
immunization with the CD4^gp120 complex in Syntex adju-
vant (oil-in-water emulsion similar in composition to MPL)
allowed the production of neutralizing anti-gp120 mAbs [14],
most of which were completely unable to bind denatured
gp120. The authors argued that this pattern of reactivity
was the result of the CD4^gp120 complex interaction, which
preserved the conformational structure of gp120. However,
they did not discuss a potential in£uence of the nature of
the adjuvant as another potential reason. Thus, based on
our experimental results we postulate that the aqueous nature
of the MPL+TDM adjuvant system is the key factor for pre-
serving the native conformation of the viral transcriptional
regulator during the immunization process.
Since blocking of the interaction of DNA-binding proteins
to their speci¢c recognition sequences is a known antibody
activity [15^16], we tested the ability of our conformation-
sensitive anti-E2C mAbs to interfere with the transcription
factor binding to its cognate oligonucleotide in an electropho-
retic gel-shift binding assay. As shown in Fig. 3A, the £uo-
rescein-labeled site 35 18 bp oligonucleotide band is shifted
upon E2C binding (lane 2). Of the six anti-E2C mAbs as-
sayed, mAbs ED5, ED12 and ED23 were able to produce a
supershift of the E2C:FITC^site 35 complex band (lanes 3^5
for ED5 as an example), indicating that these mAbs bind an
epitope non-related to the E2C DNA-recognition surface. In
contrast, the other three anti-E2C mAbs interfere with the
band shift produced by E2C (lanes 6^8 for ED13 as an exam-
ple), producing an increase of the free oligonucleotide band.
To further con¢rm this result, we analyzed the e¡ect of the
mAbs on E2C binding to immobilized biotinylated site 35 in a
biosensor cuvette. Addition of E2C to the immobilized oligo-
nucleotide produces an increase in the signal indicating spe-
ci¢c binding. Pre-incubation of E2C with mAb ED5 produces
a concentration-dependent increase in the signal obtained for
the protein:DNA complex, being two-fold higher at equimo-
lar protein:antibody concentration (Fig. 3B). This increase
clearly indicates the generation of a ternary complex, since
in a biosensor the signal is proportional to the molecular
weight of the interacting macromolecule. The same results
were obtained with mAb ED23 (data not shown). On the
contrary, pre-incubation of E2C with mAbs ED13, ED15
and ED19 leads to a concentration-dependent inhibition of
binding observed as a decrease in the signal (Fig. 3B,C).
Moreover, di¡erent inhibitory concentrations (IC50) were
found for each mAb, probably due to distinct a⁄nity con-
stants (see Fig. 3D). Thus, these antibodies are able to e⁄-
ciently inhibit E2C binding to DNA, suggesting they recog-
nize an epitope on or overlapped to the DNA-binding surface
of the transcription factor.
As demonstrated above, mAb ED23 binds a continuous
epitope comprising the residues 349^358. This epitope is lo-
cated at the opposite side of the DNA-combining site of E2C
and includes a turn and a L-strand (see red areas in Fig. 4A).
Besides, this mAb produces a strong inhibition on HRP-la-
beled ED5 IgG binding to E2C in an ELISA assay (results not
shown), suggesting that mAb ED5 recognizes an epitope over-
lapped to that of mAb ED23. In agreement with this, gel
¢ltration experiments demonstrated that these mAbs recog-
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Fig. 2. A: ELISA reactivity of anti-E2C mAbs against the native
and heat-denatured forms of E2C. Sera from unimmunized (C) and
hyperimmunized (HS) mouse were used as controls. B: mAb reac-
tivity against E2C peptides. Peptide amino acid assignment was per-
formed according to the PDB database [12]. mAbs ED12, 13, 15
and 19 showed the same pattern of reactivity as ED5 (data not
shown). FA, serum from an E2C/FA-immunized mouse. Ascitic £u-
ids of the di¡erent mAbs and control sera were used at 1/100 dilu-
tion.
FEBS 26894 6-1-03 Cyaan Magenta Geel Zwart
M.L. Cerutti et al./FEBS Letters 534 (2003) 202^206204
nize a repeated epitope on the homodimeric transcription fac-
tor (data not shown), pointing out to the highlighted red
surfaces (Fig. 4). In contrast, DNA-binding interfering
mAbs should recognize an epitope that coincides or overlaps
with the DNA-binding surface of the protein. As illustrated in
the ¢gure, this surface forms a continuous area with two sym-
metric protruding K-helices (yellow-colored residues). Taken
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Fig. 3. A: Interaction of anti-E2C mAbs with the E2C:DNA complex in an electrophoretic mobility shift assay. E2C protein (2.5 WM) was in-
cubated with 1.0, 2.0 and 4.0 WM antibody combining sites for 2 h prior 5P £uoresceinated-site 35 probe (2.5 WM) addition (C), a non-related
IgG at 4 WM. B: E¡ect of antibody:E2C interaction on protein:DNA complex formation as measured by a biosensor. Percentual response of
E2C binding to the immobilized oligonucleotide after incubation with increasing amounts of anti-protein mAbs. mAbs ED5 and ED13 are
shown as examples (see Section 2). C: IAsys raw data for di¡erent concentrations of mAb ED19 are depicted as an example to illustrate the
inhibitory e¡ect of anti-E2C mAbs on DNA binding. D: Table showing the observed IC50 for the di¡erent anti-E2C mAbs. IC50 was calculated
as the IgG concentration that renders a 50% of E2C binding response as compared with the control without antibody. Pre-incubation with un-
labeled site 35 oligonucleotide leads to total inhibition, even at low nanomolar concentrations (data not shown).
6
Fig. 4. Antigenic topography of human HPV-16 E2C. Graphical
models of free (panels A and B) and DNA-bound (panel C) HPV-
18 E2 homologous protein, indicating two clearly de¢ned surface
areas based on antibody recognition. Diagrams were generated using
Turbo Frodo and the ViewerProTrial 42 software from deposited
crystallographic coordinates [17]. The repetitive ED5-like recognition
area is colored in red (residues 351^360 in the HPV-18 E2 protein).
Residues of E2C that contact DNA are highlighted in yellow. A:
Ribbon representation of the HPV-18 E2 DNA-binding domain.
B,C: Space-¢ll representation colored as in A.
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together, these results suggest that we have obtained two dif-
ferent anti-E2C mAbs populations, depending on which of the
two major surfaces of the transcriptional regulator they rec-
ognize.
In the last years, a preliminary characterization of polyclon-
al antibodies against overlapping synthetic peptides covering
this protein has been reported [18]. mAbs against the homol-
ogous BPV-1 E2 protein have also been produced and tested
for their ability to interfere with E2 functions in vivo and in
vitro [15]. Among these antibodies, only one mAb directed
against the C-terminal domain was able to inhibit E2 binding
to DNA. Furthermore, concentration-dependent inhibition of
DNA replication in vitro by this antibody was also observed.
Interruption of transcription factor DNA binding by antibod-
ies may have at least two explanations [16,19]. First, steric
hindrance of the DNA-binding domain by the antibody may
block its interaction with DNA. Second, antibody binding
might prevent essential conformational changes in the tran-
scription factor that would be required for its biological func-
tions. Further analyses of these protein^protein interactions
are needed to understand the e¡ect these mAbs produce over
E2. Moreover, structural studies of these complexes would be
the basis for rational design strategies aimed at developing
therapeutic compounds [20] that modify binding of E2 to its
speci¢c recognition sequences on the papillomavirus genome.
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